Anastasia S.
- Country
- Greece
- Department
- Hematology Department of Clinical Pathology
Research Overview
Data & Insights
Has run more than one trial at 0 of 9 partner sites.
Specializations
Breast Cancer and Endocrine Therapy
Anastasia Sioni’s clinical research activity is strongly centered on breast cancer, with emphasis on hormone receptor-positive, HER2-negative, ER-positive, and PIK3CA-mutated disease across early, locally advanced, and metastatic settings. Her work also includes triple-negative breast cancer and recurrence-focused treatment strategies.
- Advanced and metastatic breast cancer
- ER+/HER2- early breast cancer
- Triple-negative breast cancer
- Endocrine-based therapy
- HER2-targeted breast cancer treatment
Her therapeutic interest extends to endocrine therapy, CDK4/6 inhibitor-based combinations, and PI3K pathway-directed approaches in breast malignancies.
Lung Cancer and Thoracic Oncology
Her clinical trial involvement includes a broad spectrum of non-small cell lung cancer and small cell lung cancer, covering relapsed, metastatic, limited-stage, and resected disease. She is also engaged in studies addressing molecularly defined thoracic tumors such as RET fusion-positive, KRAS G12C-mutant, and EGFR-mutated lung cancer.
- Non-small cell lung cancer
- Small cell lung cancer
- RET fusion-positive NSCLC
- KRAS G12C-mutant NSCLC
- Uncommon EGFR mutations
Her therapeutic focus in this area includes immunotherapy, targeted therapy, and novel antibody-drug conjugate strategies for thoracic oncology.
Gastrointestinal and Hepatobiliary Malignancies
Her research landscape also covers gastric cancer, gastroesophageal junction cancer, and colorectal cancer, with additional interest in locally advanced or metastatic urothelial carcinoma and advanced solid tumors with defined molecular features. This reflects involvement in treatment development for aggressive gastrointestinal cancers.
- Gastric and gastroesophageal junction cancer
- Colorectal cancer
- Urothelial carcinoma
- FGFR2b-overexpressing disease
- KRAS-mutant colorectal cancer
Her therapeutic interests include HER2-directed therapy, FGFR-targeted treatment, and combination regimens for advanced gastrointestinal malignancies.
Hematologic Malignancies and Treatment Support
As a member of the Hematology Department, she is involved in studies in multiple myeloma and in supportive care for patients receiving systemic anticancer therapy. Her portfolio includes management of chemotherapy-induced thrombocytopenia, linking hematologic care with ongoing cancer treatment.
- Multiple myeloma
- Chemotherapy-induced thrombocytopenia
- Supportive hematology in oncology
- Bone marrow and blood-based disease monitoring
- Oncology treatment continuity
Her therapeutic involvement spans anti-myeloma therapy and strategies that preserve delivery of planned cancer treatment in patients with hematologic complications.
Prostate Cancer, Biliary Disease, and Symptom Control
Her clinical research interests further include metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and primary biliary cholangitis. She also participates in work addressing low back pain in adult patients, adding a symptom-management dimension to her oncology and medical portfolio.
- Metastatic prostate cancer
- Primary biliary cholangitis
- Low back pain
- Advanced solid tumor care
- Supportive symptom treatment
Her therapeutic focus includes hormonal treatment strategies in prostate cancer, hepatobiliary disease management, and relief of disabling pain symptoms in adult patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.